| This week's sponsor is TD2. | | | |
Featured Story | | | Monday, June 5, 2017 In a late-stage study presented at ASCO, Hutchison China MediTech’s VEGF inhibitor fruquintinib showed it could help relapsed patients with advanced colorectal cancer live longer, delivering a median overall survival of 9.3 months compared with 6.57 months for patients on placebo. |
|
|
| This week's sponsor is Althea. | | | |
Top Stories Tuesday, June 6, 2017 Flex Pharma is on the lookout for a new chief after co-founder Christoph Westphal, M.D., Ph.D., is stepping down from his CEO role. Tuesday, June 6, 2017 Several months after abandoning plans for a securities offering, Israel’s Bioblast Pharma has asked JSB-Partners to help it seek out a partner/merger to help lift it out of its troubles. Monday, June 5, 2017 As the technology landscape of clinical trials evolves, apps are engaging patients in new ways and in real time, thus becoming an integral part of the healthcare infrastructure. Tuesday, June 6, 2017 Texas startup Lung Therapeutics has got off a $14.3 million series B round as it eyes the cash boost for its trials in fibrosis, lung injury and disease. Tuesday, June 6, 2017 Patrick Soon-Shiong announced at ASCO that NantKwest “expands [the] NANT cancer vaccine program,” although it hasn't yet. Monday, June 5, 2017 Sleep diagnostics player Somnarus presented data this weekend showing that its disposable adhesive patch effectively detected obstructive sleep apnea of all severity levels. The patch could be an alternative to portable sleep monitors currently used to diagnose the disorder. Monday, June 5, 2017 Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine back in 2010. Years later, the company has unveiled new data showing the med generates a killer T-cell response—and the strength of that response correlates with overall survival. Tuesday, June 6, 2017 CEO Christophe Weber has projected that new oral multiple myeloma drug Ninlaro, a first-to-market active proteasome inhibitor, is on course to be Takeda's best-selling cancer drug. To stay ahead of that success, the Japanese drugmaker is starting work on a new plant in Ireland to manufacture it. | | | AstraZeneca's VP and therapeutic area head of cardiovascular/metabolism Steven L. Zelenkofske has become the new CMO at gene therapy biotech uniQure, succeeding Christian Meyer. Statement MaxCyte has penned a new cooperative R&D agreement with the NIH's National Institute of Allergy and Infectious Diseases to work on therapies for X-linked chronic granulomatous disease using next-gen gene correction with CRISPR-Cas9. Release Swiss biotech Axovant Sciences announced several key senior management changes to strengthen its executive team, including hiring Eric Floyd as senior VP of regulatory affairs and promoting Shankar Ramaswamy to a new role of VP of global medical affairs. Statement | |
|
Resources Sponsored by Envigo Performing a sophisticated surgery to create a myocardial infarction model. Join us on June 7th at 11:00 AM EDT. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. FierceBiotech Executive Breakfast- Tackling the Drug Price Problem: A Town Hall Debate June 21, 2017 | San Diego, CA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA 2017 BIO International Convention: The Largest Global Biotech Partnering Event of the Year June 19-22 | San Diego, CA Join 1,000 Diagnostics Professionals at Next Generation Dx Summit August 15-18, 2017 | Washington, DC | 